1. Home
  2. FNWB vs MAIA Comparison

FNWB vs MAIA Comparison

Compare FNWB & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Northwest Bancorp

FNWB

First Northwest Bancorp

HOLD

Current Price

$10.19

Market Cap

82.0M

Sector

Finance

ML Signal

HOLD

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

HOLD

Current Price

$1.27

Market Cap

86.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FNWB
MAIA
Founded
1923
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
82.0M
86.2M
IPO Year
2012
2022

Fundamental Metrics

Financial Performance
Metric
FNWB
MAIA
Price
$10.19
$1.27
Analyst Decision
Buy
Analyst Count
1
0
Target Price
$13.50
N/A
AVG Volume (30 Days)
63.8K
758.6K
Earning Date
05-05-2026
05-08-2026
Dividend Yield
0.68%
N/A
EPS Growth
36.00
33.33
EPS
N/A
N/A
Revenue
$176,000.00
N/A
Revenue This Year
$19.24
N/A
Revenue Next Year
$8.90
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.05
$0.87
52 Week High
$10.98
$3.19

Technical Indicators

Market Signals
Indicator
FNWB
MAIA
Relative Strength Index (RSI) 65.33 41.68
Support Level $9.26 $1.26
Resistance Level $10.33 $1.50
Average True Range (ATR) 0.33 0.10
MACD 0.08 0.02
Stochastic Oscillator 84.96 34.69

Price Performance

Historical Comparison
FNWB
MAIA

About FNWB First Northwest Bancorp

First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It offers various products and services, such as commercial business loans, multi-family real estate loans, auto and consumer loans, transaction accounts, savings and money market accounts, online banking services, etc., focused on the lending, deposit, and money movement needs of individuals, businesses and nonprofit organizations. The Group's operations are mainly focused on serving various communities in Washington State, U.S. Substantially all of its income is derived from a diverse base of commercial, mortgage, and consumer lending activities and investments.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

Share on Social Networks: